Core Viewpoint - The collaboration between Guangdong and Macau in the biopharmaceutical and health industry is being promoted through a new model of "Macau R&D + Hengqin Transformation + Guangdong Manufacturing," aiming for high-quality development and internationalization of the industry [1][2][5]. Group 1: Industry Development - The Guangdong-Hong Kong-Macau Greater Bay Area is recognized as a strategic region with significant potential for the biopharmaceutical and health industry [3]. - Guangdong aims to cultivate a biopharmaceutical and health industry cluster with a target scale of 1 trillion yuan by 2027, with the industry cluster generating 663.8 billion yuan in revenue in 2023 [2]. - The Hengqin Guangdong-Macau Deep Cooperation Zone has introduced several supportive measures to promote the high-quality development of the biopharmaceutical and health industry [4]. Group 2: Collaborative Mechanisms - The collaboration focuses on leveraging Macau's international market access and Guangdong's manufacturing capabilities to enhance the biopharmaceutical sector [1][6]. - The "Macau Registration + Hengqin Production" model is encouraged to standardize and internationalize the development of traditional Chinese medicine, innovative drugs, and medical devices [5][6]. - The establishment of the Guangdong-Macau Traditional Chinese Medicine Science and Technology Industrial Park is seen as a key platform for promoting internationalization [5]. Group 3: Economic Impact - The Hengqin Cooperation Zone reported a GDP of 26.313 billion yuan in the first half of the year, with a year-on-year growth of 5%, indicating robust economic activity [4]. - Retail sales in the region reached 2.49 billion yuan, showing a significant year-on-year increase of 42.1%, while total import and export volume surged by 101.5% [4]. Group 4: Market Expansion - The collaboration aims to deepen trade relations with Portuguese-speaking countries and countries involved in the Belt and Road Initiative, enhancing the international market for biopharmaceuticals [6]. - The "Hong Kong-Macau Drug and Medical Device Pass" policy facilitates the free flow of drugs, devices, and patients within the Greater Bay Area, promoting regional medical integration [6][7].